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Abstract
Background: In Tanzania, HIV-1 RNA testing is rarely available and not standard of care. Determining virologic failure is
challenging and resistance mutations accumulate, thereby compromising second-line therapy. We evaluated durability
of antiretroviral therapy (ART) and predictors of virologic failure among a pediatric cohort at four-year follow-up.
Methods: This was a prospective cross-sectional study with retrospective chart review evaluating a perinatally
HIV-infected Tanzanian cohort enrolled in 2008-09 with repeat HIV-1 RNA in 2012-13. Demographic, clinical, and
laboratory data were extracted from charts, resistance mutations from 2008-9 were analyzed, and prospective HIV
RNA was obtained.
Results: 161 (78%) participants of the original cohort consented to repeat HIV RNA. The average age was 12.2 years
(55% adolescents ≥12 years). Average time on ART was 6.4 years with 41% receiving second-line (protease inhibitor based)
therapy. Among those originally suppressed on a first-line (non-nucleoside reverse transcriptase based regimen) 76%
remained suppressed. Of those originally failing first-line, 88% were switched to second-line and 72% have suppressed
virus. Increased level of viremia and duration of ART trended with an increased number of thymidine analogue mutations
(TAMs). Increased TAMs increased the odds of virologic failure (p = 0.18), as did adolescent age (p < 0.01).
Conclusions: After viral load testing in 2008-09 many participants switched to second-line therapy. The majority
achieved virologic suppression despite multiple resistance mutations. Though virologic testing would likely hasten
the switch to second-line among those failing, methods to improve adherence is critical to maximize durability of ART
and improve virologic outcomes among youth in resource-limited settings.
Keywords: Pediatric HIV, HIV resistance, Thymidine analogue mutations, ART adherence, HIV RNA, Durability of
antiretroviral therapy, Viral load
Background
An estimated 3.4 million children between 0-14 years of
age are living with HIV, of whom 91% live in sub-Saharan
Africa [1]. Though a 35% decline in new pediatric HIV
infections is reported for children under 15 years in 2012,
an estimated 260,000 children a year continue be newly
diagnosed with HIV [2,3]. Despite a continued anti-
retroviral therapy (ART) treatment gap for children in
resource-limited settings, the number of HIV-infected
children initiating ART is increasing [3]. This scale up
has improved the prognosis of perinatally HIV-infected
children with an unprecedented number now surviving
into adolescence and adulthood. However, challenges
remain in preserving the durability of ART. Such chal-
lenges include the fact that children require complex
dosing formulations as they grow, they are at increased
risk of virologic failure due to high initial viral loads,
and they need to preserve regimen efficacy over an
entire lifetime. For these reasons and concerns regarding
adherence, children tend to continue on failing regimens
longer than adults [4].
Therapeutic monitoring poses an additional challenge
as HIV-1 RNA (viral load) testing is frequently unavail-
able in resource-limited settings. Unsuppressed viremia
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leads to accumulation of resistance mutations and patients
monitored by clinical or immunologic criteria tend to have
increased durations of unsuppressed viremia compared to
those monitored with viral load [5]. Despite this limitation,
a majority of adults in resource-limited settings have
attained virologic suppression on second-line regimens,
even in the context of clinical or immunologically driven
monitoring strategies [6,7]. The utility and cost/benefit of
obtaining viral load and/or resistance profiles in such
settings is controversial [8-10].
In Tanzania, an estimated 230,000 children between
0 – 14 years of age are living with HIV, and according
to UNICEF only approximately 26% receive ART [11].
Patients are monitored by immunologic (CD4) and clinical
criteria, as HIV-1 RNA testing is rarely available and not
standard of care. Therefore, determining ART failure is
challenging and may result in accumulation of resistance
mutations that could compromise second-line therapy.
Understanding the frequency of virologic failure and
resistance mutations will provide important informa-
tion regarding the prognosis of HIV-infected youth in
resource-limited settings and may provide insights into
optimal first and second-line regimens [12].
In 2008-9, our research team enrolled 206 Tanzanian
children in a cross-sectional study to evaluate the preva-
lence of virologic failure and associated risk factors [13].
Among this cohort, only five children had received pre-
vention of mother-to-child transmission (PMTCT) and
the majority of participants were receiving first-line ther-
apy. The present study re-examined virologic outcomes
in this pediatric cohort four years later (2012-13), and it
evaluated associations with virologic failure after a portion
of the cohort had switched to second-line therapy. These
data provide a unique opportunity to evaluate the long-
term durability of ART among children and adolescents
in a resource-limited setting without standard access to
virologic monitoring.
Methods
This study re-enrolled participants who previously enrolled
in a cross-sectional study to evaluate the prevalence of
virologic failure among perinatally HIV-infected Tanzanian
children receiving ART and to document associations
with virologic outcomes. Methods of enrollment in the
initial study have been described elsewhere [13]. Briefly,
in 2008-9, HIV-infected children between 12 months to
16 years of age (median age 7 years) who had received
ART for a minimum of six months were enrolled from
Kilimanjaro Christian Medical Centre (KCMC), the
largest pediatric HIV treatment center in the Northern
Zone of Tanzania. At that time, first-line therapy consisted
of zidovudine (AZT) or stavudine (d4T), lamivudine
(3TC), and a non-nucleoside reverse transcriptase
inhibitor (NNRTI), either nevirapine (NVP) or efavirenz
(EFV). For those requiring second-line therapy, stand-
ard of care consisted of substituting the NNRTI with
lopinovir and boosted ritonavir (LPV/r) and prescribing
didanosine (ddI) or 3TC with abacavir (ABC).
Between 2012-13, we re-enrolled the same cohort and
obtained a repeat HIV-1 RNA to determine long-term
durability of ART, including efficacy and predictors of
failure. Didanosine was phased out in 2012-13 such that
the majority of those on second-line currently receive
ABC, 3TC and LPV/r.
Data collection and laboratory methods
Participant sociodemographic data, ART regimen, CD4+
cell count, opportunistic infections, World Health Organ-
ization (WHO) staging, and physician-reported adherence
were retrospectively collected from patient charts and
research case report forms. Physician-reported adherence
was recorded from progress notes and the standardized
HIV form used in care and treatment centers (CTC)
across Tanzania. This form has a dedicated column to
assess adherence in which physicians document “G” for
good and “P” for poor adherence. Poor is defined as miss-
ing two or more doses of medication by self-report during
the previous month and is reassessed monthly. Adherence
was coded as poor for this study if the physician docu-
mented two or more “P’s” in their progress notes or on
the standard CTC form in the year preceding the partici-
pant’s HIV-1 RNA measure.
All participants underwent plasma HIV-1 RNA quantifi-
cation. HIV RNA testing was performed at the Kilimanjaro
Christian Research Institute (KCRI) Biotechnology Lab
using the Abbott m2000 (Des Plaines, IL) with 40
copies/mL as the lower limit of detection. Due to a
mechanical failure of the instrument at the KCRI
laboratory, specimens collected between January to
March 2013 were sent for HIV-1 RNA quantification to the
Bio Analytical Research Corporation (BARC) laboratory.
BARC is KCRI’s U.S. Division of AIDS approved back-up
laboratory in Cape Town, South Africa. Both laboratories
participate fully in international external quality assurance
programs including Viral Quality Assurance. CD4+ cell
counts were tested in the clinical laboratory at KCMC per
the standard of care.
Plasma samples from the original 2008-9 enrollment
with HIV-1 RNA >1,000 copies/mL were sent to Duke
University Medical Center (Durham, NC) for genotypic
ART resistance testing and HIV subtyping. These tests
were performed in 2009 by directly sequencing the PCR
products. All HIV-1 RNA levels obtained as part of the
study, both in 2008-9 and again in 2012-13, were made
immediately available to the treating provider, but the
resistance data were utilized strictly for research purposes.
Interim HIV-1 RNA testing was sporadically available by
private donation and/or support from Elizabeth Glaser
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Pediatric AIDS Foundation for patients felt to be at high
risk for virologic failure. The decision to switch from a
first-line to a second-line regimen was at the discretion of
the treating physician. NRTIs were chosen according to
Tanzanian guidelines.
Analysis
Descriptive statistics were used to describe the age
(continuous and categorical), gender, time on ART, ART
regimen, adherence, WHO stage, and CD4+ cell count
(continuous and categorical) according to WHO cutoffs.
Logistic regression was used to determine univariate
associations between virologic failure (defined as HIV-1
RNA >400 copies/mL) and key demographic and clinical
covariates as itemized above. Any covariates with p < 0.2
on univariate analyses were incorporated into a multire-
gression model. Continuous variables were preferentially
used in the multivariate model if no significant differ-
ence was demonstrated between models with continuous
versus categorical variables using the likelihood ratio test.
Stata 13.1 (College Station, TX) was used for statistical
analyses.
HIV-1 subtypes were described and resistance data
analyzed using the Stanford University drug resistance
database to predict low, intermediate, or high level resist-
ance to ART [14]. The number of thymidine analog
mutations (TAMs) was also analyzed as a proxy for time
on a failing ART regimen and predictor of suppression on
second-line therapy.
Ethical review and informed consent
Written informed consent was required from a parent
or guardian of children aged <18 years of age with assent
from children aged 13 years or older. Those 18 years
and older were able to consent for themselves. The Duke
University Institutional Review Board, the KCMC Research
Ethics Committee, and the Tanzanian National Institute
Medical Review approved the study protocol.
Results
Of the 206 participants originally enrolled, 161 (78.2%)
consented for this follow-up study (Figure 1). Nineteen
(9.2%) were lost to follow up, 13 (6.3%) transferred to other
clinics, 9 (4.4%) remained in attendance at the original
clinic but a parent or guardian was unavailable for consent,
and 4 (1.9%) were known to have died. Compared to those
who were retained in follow up, the 45 children whose
data was not available for follow up had similar baseline
characteristics, including age, use of second line therapy,
and history of virologic failure (p > 0.4 for all).
Descriptive characteristics of the 161 participants with
complete follow up information are summarized in Table 1.
The median age was 12.2 years; 55.3% were 12 years or
older (referred to as adolescents). The cohort was 52.2%
female with an average CD4+ of 829 cells/microL and had
received ART for an average of 6.4 years. Slightly more than
half were receiving a first-line regimen: AZT (8 participants
were instead receiving d4T which began phase out in 2012)
and 3TC plus NVP (37.3%) or EFV (21.1%), while 41% were
receiving second-line therapy. Those currently receiving
second-line therapy had been receiving it for an average of
3.5 years (IQR 3.1 – 4.2). Physician-reported adherence
was documented as poor in 24.8% of participants. When
categorized by age, 11/72 (15.3%) of children less than
12 years of age had physician-documented poor adherence
as compared to 29/89 (32.6%) of adolescents (p = 0.01).
The majority (85.0%) were WHO Stage III or Stage IV at
the time of ART initiation.
For the 161 participants with viral loads available both
from 2008-9 and 2012-13, results were compared in
Figure 2. The majority of participants, 149/161 (92.5%)
were receiving first-line therapy in 2008-9. Of those
originally suppressed on first-line, 74/97 (76%) remained
suppressed and on first-line treatment at the time of
repeat HIV-1 RNA in 2012-13. Of the 52 participants
unsuppressed on first-line therapy in 2008-9, 46 (88%)
switched to second-line therapy and 33/46 (72%) had
Figure 1 Description of cohort past to present.
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suppressed virus in 2012-13. Of the six who were not
switched, all but one continued to fail on a first-line
regimen. Of the eight who switched in the interim of
the two studies, 3 did so due to immunologic failure, 3
due to virologic failure, 1 due to clinical failure, 1 for
reasons that are unclear from chart review. Considering
death, loss to follow up, and those who were unable to
re-consent for testing (excluding transfers) to represent
current virologic failure, a majority who enrolled in
2008-09, 118/193 (61.1%) remain suppressed on ART.
Durability of first-line ART was evaluated by age. Of
those who remained less than 12 years of age at both
assessments (2008-9 and 2012-13), 37/39 (95%) who
continued to receive first-line were suppressed and 63/
72 (88%) were recently suppressed with any regimen. Of
the children who transitioned into adolescence between
the 2008-9 and 2012-13 assessments, 28/34 (82%)
remained suppressed on first-line, with 44/65 (68%)
suppressed on any regimen. Finally, those who were
12 years or older for the duration of the study, 9/15
(60%) remain suppressed on first-line therapy, with 11/
24 (46%) suppressed on any regimen. Compared to those
who remained under 12 years of age, there was a 3.3 fold
increased odds of virologic failure on any regimen during
transition to adolescence (p < 0.01), and an 8.3 fold
increased odds of failure for those receiving any ART
regimen who remained in adolescence (p < 0.01).
Adherence to ART was also evaluated by age. Com-
pared to those who remained less than 12 years old,
those who transitioned into adolescents during this
study had a 2.3 fold increased odds of poor adherence
(p = 0.05). Those who were 12 years of age or older
throughout the study (since 2008-09) demonstrated a 4
fold increased odds of poor adherence (p < 0.01).
Table 1 Sociodemographic and clinical characteristics of 161 participants stratified by current HIV-1 RNA
Total (N = 161) HIV-1 RNA <400 copies/mL (N = 118) HIV-1 RNA ≥400 copies/mL (N = 43)
Gender, N (%)
Male 77 (48%) 60 (51%) 17 (40%)
Female 84 (52%) 58 (49%) 26 (60%)
Age (IQR) years 12.2 (9.3 – 15.3) 11.6 (8.8 – 14.6) 13.8 (12.3 – 16.2)
Age (categorical) years
Child (≤12 years old) 72 (45%) 63 (53%) 9 (21%)
Adolescent (>12 years old) 89 (55%) 55 (47%) 34 (79%)
Time on Treatment (IQR) years 6.4 (5.3 – 7.5) 6.3 (5.2 – 7.4) 6.6 (5.5 – 7.6)
1st Line Regimen AZT or (d4T) +3TC + EFV 35 (21%) 28 (24%) 6 (14%)
AZT or (d4T) + 3TC + NVP 60 (37%) 47 (40%) 13 (30%)
2nd Line Regimen ABC +3TC + LPV/r 66 (42%) 43 (36%) 24 (56%)
Adherence as reported by physician, N (%)
Good 121 (75%) 99 (84%) 22 (51%)
Poor 40 (25%) 19 (16%) 21 (49%)
WHO Stage
I 2 (1%) 2 (2%) 0
II 22 (14%) 19 (16%) 3 (7%)
III 92 (57%) 64 (54%) 28 (65%)
IV 45 (28%) 33 (28%) 12 (28%)
+Original HIV-1 RNA, logcopies/mL (IQR) 1.8 (0 – 5.9) 1.6 (0 –5.3) 2.2 (0 – 5.4)
CD4 mean absolute number (IQR) 829 (538 – 1099) 929 (660 – 1160) 530 (224 –784)
++CD4 absolute number by category
CD4 < 200, N (%) 9 (5%) 3 (3%) 6 (14%)
CD4 201-349, N (%) 13 (8%) 4 (3%) 9 (21%)
CD4 350 – 499, N (%) 13 (8%) 7 (6%) 6 (14%)
CD4≥ 500, N (%) 112 (70%) 96 (81%) 16 (37%)
CD4 missing, N (%) 14 (9%) 8 (7%) 6 (14%)
+HIV-1 RNA from 2008-09 log transformed; ++CD4 categories as defined by WHO.
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Subtype and resistance mutations
Resistance data were available for 35/54 (65%) originally
failing first-line therapy in 2008-9 (Table 2). Subtypes A
and D were most prevalent with no significant difference
between those who eventually suppressed virus versus
those found to be in virologic failure in 2012-13. Key NRTI
mutations included M184V in 31/35 (89%) individuals and
one or more TAMs present among 17/35 (49%). The
following TAMs were identified: T215F/Y (31%), M41L
(11%), L210W (9%), D67N (9%), K70R (11%), K219Q
(3%). NNRTI mutations were found in 31/35 (89%)
individuals, including K103N (40%) and Y181C (23%).
The K65R mutation was not found.
Based on genotype, intermediate resistance to NRTI’s
including ABC and ddI was predicted in 10/35 (29%)
participants, of whom 4/10 (40%) fully suppressed on a
second-line regimen. The other six were failing second-
line, two with reported good adherence. Two patients
had high predictive resistance (6 TAMs and 3 TAMs
respectively) and both were fully suppressed on second-
line with good physician-reported adherence.
Among participants who changed to second-line ther-
apy and who had no TAMs, 83% suppressed virus,
whereas 60% with one TAM and 57% with two or more
TAMs suppressed virus (Figure 3). Those with no TAMs
had been receiving ART for an average of 2.1 years as
compared to 2.4 years for those who accumulated TAMs
(p = 0.6). The ability to suppress virus based on those with
and without TAMs did not reach statistical significance
(p = 0.15). Comparison of the level of viremia at the
time of original viral load (mean = 4.51 log10 copies/mL)
to the presence of any TAMs demonstrated a significant
4.85 increased odds of having TAMs for every log increase
in viremia (p < 0.01).
Univariate and multiregression analysis
Univariate analyses demonstrated older age (OR 4.3,
p < 0.01), physician-reported poor adherence (OR 5.0
Figure 2 Comparison of HIV RNA results from 2008-09 and 2012-13 for 161 participants.
Table 2 Genotypic data from participants with HIV





copies/mL (N = 25)
HIV-1 RNA ≥ 400
copies/mL (N = 10)
Subtypes
A 12 (35%) 8 (32%) 4 (40%)
B 1 (3%) 1 (4%) 0
C 5 (14%) 4 (16%) 1 (10%)
D 11 (31%) 8 (32%) 3 (30%)
Recombinant
(A/C; A/D; D/C; K/C)
6 (17%) 4 (16%) 2 (20%)
NRTI
M184V 31 (89%) 22 (88%) 9 (90%)
TAMs
0 TAMs 18 (51%) 15 (60%) 3 (30%)
1 TAM 10 (29%) 6 (24%) 4 (40%)
≥ 2 TAMs 7 (20%) 4 (16%) 3 (30%)
NNRTI
K103N 14 (40%) 9 (36%) 5 (50%)
Y181C 8 (23%) 5 (20%) 3 (30%)
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p < 0.01), and lower CD4 (OR 0.997 per incremental
increase in CD4 count p < 0.01) to be significantly associ-
ated with virologic failure (Table 3). While not statistically
significant, children with virologic failure were more likely
to be female, to be receiving second-line ART, and to
have TAMs. Multiregression analysis was run for all
variables with p < 0.2 in univariate analyses including:
age, adherence, CD4+ cell count, original HIV-1 RNA log
transformed, and TAMs. No variables remained significant
to p < 0.05 on multivariate analysis (Table 3).
Discussion
Our study documented clinical and virologic outcomes
among youth receiving ART with follow up including
Figure 3 Thymidine analog mutations as a predictor of virologic suppression.
Table 3 Associations with virologic failure (HIV-1 RNA >400 copies/mL) in 2012-13; univariate and multivariate analysis
Univariate analysis Multivariate analysis
Characteristic in 2012-13 Odds ratio P value Confidence interval Odds ratio P value Confidence interval
Female 1.582 0.205 0.778 – 3.218
Age continuous (years) 1.223 <0.001 1.093 – 1.369 1.031 0.860 0.733 - 1.449
Age categorical (>12 years) 4.327 <0.001 1.908 – 9.814
Time on Treatment 1.190 0.217 0.903 – 1.569
Regimen 1st line AZT (d4T) +3TC + EFV 1 (reference)
AZT (d4T) +3TC + NVP 1.291 0.642 0.441 – 3.780
2nd line ABC +3TC + LPV/r 2.605 0.064 0.946 – 7.175
Adherence (Poor) as reported by physician 4.974 <0.001 2.295 – 10.781 2.371 0.439 0.267 - 21.073
*Original HIV-1 RNA, log10copies/mL 1.148 0.108 0.970 – 1.357 1.765 0.324 0.570 – 5.467
CD4 continuous (mean) variable 0.997 <0.001 0.996 – 0.998 0.997 0.083 0.994 - 1.000
CD4 Categorical: <200 1 (reference)
CD4 201-349 1.125 0.889 0.183 – 6.935
CD4 350 - 499 0.429 0.346 0.073 – 2.500
CD4≥ 500 0.083 0.001 0.019 – 0.367
TAMs:
0 1 (reference)
1 3.333 0.183 0.567 – 19.593 2.349 0.458 0.247 – 22.376
≥ 2 3.75 0.183 0.537 – 26.188 3.376 0.502 0.096 - 118.12
*This is the Original 2008-09 HIV-1 RNA.
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over three quarters (78.2%) of the original cohort over a
four-year period. Of the 161 participants, 73.3% were
virologically suppressed at four-year follow-up. These
numbers are similar to data from a prospective study in
Uganda evaluating children initiating ART with regular
viral load monitoring which demonstrated an average of
74% virologic suppression (HIV RNA <400 copies/mL)
over 3 years. While only 11/108 (10%) switched to
second-line therapy, all suppressed in that study [15].
In our study, a substantial proportion of participants
were identified with virologic failure in 2008-09 and
were switched to second-line therapy such that 40.9%
were receiving second-line therapy at four-year follow-
up. Of note, few participants were switched in the
interim period between 2008-09 to the follow up study
in 2012-13, a time when virologic testing was not
readily available. Though a majority were virologically
suppressed, approximately one-third (34.8%) of those
receiving second-line were not suppressed at follow up,
a particularly concerning finding given the lack of third-
line regimens in Tanzania.
Though viral load testing is the “gold standard” to
monitor ART response in high income countries, resource-
limited settings experience difficulty implementing this
preferred option due to cost, logistical concerns, and
technical challenges. Tanzanian guidelines continue to
rely on immunologic and clinical criteria, which have a
low sensitivity to predict virologic failure, especially in
children [13]. There is forward movement to phase in
viral load testing, though significant capacity building
will be necessary for implementation. WHO 2013 guide-
lines recommend routine viral load monitoring six
months after ART initiation and every 12 months there-
after. Most appropriate and cost conscientious monitoring
requires further research and high risk populations,
such as adolescents, may require more frequent testing
to ensure early adherence counseling and detection of
virologic failure.
This study supports increasing attention toward the
growing number of adolescents living with HIV. It dem-
onstrated that adolescents were more likely than younger
children to have both poor adherence (p = 0.01) and viro-
logic failure (p < 0.01). Reasons for poor adherence among
youth 12 years and older are often multifactorial, includ-
ing logistical complications in day-to-day routines (simply
forgetting), adverse side effects, and emotional difficulties
such as depression, traumatic stress, and anxiety [16-18].
Adolescents have been reported to demonstrate worse
adherence when compared to adults [19-21] as well as
younger children [22]. Adolescents were more likely to
be failing therapy presumably because of poor adher-
ence and potentially due to longer duration receiving
ART with accumulation of resistance mutations making
their virus more difficult to suppress.
Nearly all participants with virologic failure and resist-
ance testing harbored dual NRTI and NNRTI resistance
(89%). These data demonstrate slightly higher levels of
dual-class resistance than found in a small study in rural
Tanzania (58%) [23], and very similar findings to a recent
pediatric study in Ugandan [24]. The Ugandan study
demonstrated the virus in 90% of children failing ther-
apy contained M184V mutation, 50% had the NNRTI
mutation K103N, 23% had Y181C, and 43% had at least
one TAM (10% accumulated three or more) [24]. NRTI
mutations, especially TAMs, are significant in terms of
their influence on the success of second-line regimens in
resource-limited settings. Time on a failing ART regimen
is thought to be a predictor of accumulation of TAMs,
which then compromise second-line therapy [25,26].
Data from Uganda demonstrating very early acquisition
of M184V (1.5 months post initial viremia on ART)
compared to TAMs (12 months post viremia) suggests
if virologic failure is recognized early, prior to the accu-
mulation of TAMs, second-line therapy may be more
robust [27]. In our study, accumulation of TAMs was
non-significantly associated with higher odds of virologic
failure (p = 0.18), though power to detect a difference was
likely low.
Adherence may ultimately be the most important pre-
dictor of success of second-line therapy. Despite a high
number of TAMs, both this study and similar Ugandan
studies found a majority of children were still able to
suppress on second-line therapy [15,24].
A high level of viremia in 2008-09 did increase the odds
of having one or more TAMs (p < 0.01), but did not pre-
dict the ability to suppress at four year follow up (p = 0.11)
(Table 3). Results of the multi-national SECOND-LINE
study in adults indicate high rates of suppression (~80%)
on standard NRTI backbone second-line regimens were
non-inferior to a nucleoside-sparing regimen. This finding
offers reassurance that standard second-line therapies
have reasonable success even in settings with prolonged
periods of unsuppressed viremia [6]. Another adult study
found that approximately 22% of patients receiving
second-line therapy did not achieve HIV RNA suppres-
sion by six months, citing poor adherence rather than
HIV drug resistance as the cause of most failures [25].
This was also the interpretation of a South African study
among adults who switched to PI based second-line ther-
apy for which 25% demonstrated virologic failure at both
12 and 24 months, presumed to be due to poor adherence
and not resistance [28].
Sequencing
Consideration of optimal drugs for first and second-line
therapy is vital to maximizing the durability of ART.
While M184V is a common resistance mutation that
develops early in the majority of patients failing regimens
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with 3TC or FTC, therapeutic options remain given its
association with hyper-susceptibility to other NRTIs.
TAMs, on the other hand, tend to accumulate over a
longer period of time with a failing AZT regimen. They
are thought to convey much higher risk of regimen failure
given their association with reduced HIV susceptibility to
a number of NRTIs with no enhanced efficacy. K65R,
L74V, T215Y slowly accumulate with ABC or TDF and
do not affect susceptibility to AZT [4]. In fact, they
may induce hypersusceptibility, which can then be used
in second-line treatment [29]. For these reasons, recent
WHO guidelines now recommend ABC/3TC for those
3-10 years of age or TDF/3TC (or FTC) for those over
10 years (and ≥35 kg) plus EFV as a first-line treatment
option. Unfortunately there is currently no fixed-dose
combination of ABC/3TC/EFV to simplify this regimen
and Tanzania has not yet adopted this recommendation.
Tenofovir is now approved down to two years of age,
though lack of an appropriate and affordable pediatric
formulation and monitoring bone density and creatinine
could prove challenging [4].
Limitations
This study has several limitations. The cross-sectional
design gives a snap shot of two time points. The original
viral load does not provide information on the duration
of virologic failure prior to testing; however, by using the
accumulation of TAMs as a proxy, presumably many
individuals had a prolonged period of viral replication on
therapy. Only two-thirds of the original genotype samples
were able to amplify for resistance testing. This is likely
due to recurrent heating and cooling cycles in the storage
facility that may have compromised sample quality.
After switching to second-line, participants may have
initially suppressed, but then rebounded. Information on
this time sequence is incomplete. We do not have resist-
ance data on the recent viral load to better understand
whether maladherence versus further accumulation of
resistance, or both, were at play in those with recent
virologic failure.
Though this study was not powered to show statisti-
cally significant differences among resistance mutations
and their ability to predict suppression on second-line, it
does provide a real world example of the durability of
ART as perinatally HIV-infected children age into adoles-
cence. While ultimately no factors remained significantly
associated with virologic failure in multivariate analysis,
colinearity of factors such as adolescence and poor adher-
ence may have contributed to this finding and the results
of the univariate analysis should bear weight in consider-
ing future policies targeted towards improving adher-
ence and recognizing risk for failure.
Finally, our data reflect an “aging” population of HIV-
infected children who were largely infected before PMTCT
programs were available. While the number of new HIV
infections among HIV-exposed children is declining, the
complexity of choosing and managing ART for those who
are infected, most of whom are now nevirapine-exposed,
was not addressed in this cohort. As WHO recommenda-
tions now call for initiation of PI-based therapy in all
HIV-infected infants, the availability of future options
for ART will become increasingly critical.
Conclusions
This study provides both optimism for retention in care
and durability of virologic suppression among children
in resource-limited settings initiated on NNRTI-based
regimens. Resistance data among children in resource-
limited settings are scarce, as are the overall outcomes
of standard PI regimens as second-line in settings where
clinical and immune-based monitoring strategies are the
norm. Our data suggest that virologic monitoring may lead
to faster switch to second-line therapy resulting in fewer
resistance mutations and potentially preserve treatment
options. Nonetheless, despite accumulation of TAMs, most
patients were able to suppress on second-line therapy when
adherence was excellent. Validated methods to improve
adherence among adolescents living with HIV are urgently
needed, as is improved drug sequencing in settings where
options are limited. Improved understanding of second-line
ART is critical to maximize durability of second-line as
currently most resource-limited settings have no access
to third-line therapy.
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